June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Rescue Intra-Arterial Chemotherapy Following Retinoblastoma Recurrence After Initial Intra-Arterial Chemotherapy
Author Affiliations & Notes
  • Renelle Pointdujour Lim
    Ocular Oncology, Wills Eye Hospital, Philadelphia, PA
    Thomas Jefferson University Hospital, Philadelphia, PA
  • Emil A Say
    Ocular Oncology, Wills Eye Hospital, Philadelphia, PA
    Thomas Jefferson University Hospital, Philadelphia, PA
  • Christopher Cao
    Ocular Oncology, Wills Eye Hospital, Philadelphia, PA
    Thomas Jefferson University Hospital, Philadelphia, PA
  • Carol L Shields
    Ocular Oncology, Wills Eye Hospital, Philadelphia, PA
    Thomas Jefferson University Hospital, Philadelphia, PA
  • Footnotes
    Commercial Relationships Renelle Pointdujour Lim, None; Emil Say, None; Christopher Cao, None; Carol Shields, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 6058. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Renelle Pointdujour Lim, Emil A Say, Christopher Cao, Carol L Shields; Rescue Intra-Arterial Chemotherapy Following Retinoblastoma Recurrence After Initial Intra-Arterial Chemotherapy. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):6058.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To determine the efficacy of rescue intra-arterial chemotherapy (IAC) for tumor recurrence after previous IAC for retinoblastoma.

 
Methods
 

Retrospective interventional case series of 12 patients treated with repeat (rescue) IAC for tumor, subretinal seed or vitreous seed control after previous IAC for retinoblastoma.

 
Results
 

Median age at presentation was 16 months and 8 were female. The initial International Classification of Retinoblastoma was group B (n=1), group D (n=7), and group E (n=4). In all cases, initial IAC was delivered at Thomas Jefferson University Hospital or elsewhere using M3 (n=3) or M5 (n= 7), M5+T1 (n=2) median 3 cycles (range 1-4). Of the 12 patients, 17% (n=2) had the opposite eye previously enucleated so the rescue IAC was planned for the only remaining eye. Rescue IAC was delivered for recurrent solid tumor (n=1) recurrent extensive subretinal seeds (n=7), recurrent extensive vitreous seeds (n=1), or for combination recurrent subretinal and vitreous seeds (n=3). The median interval between final cycle of initial IAC to first cycle of rescue IAC was 4 months (range 2-10 months). IAC was successful through the ophthalmic artery (10/12, 83%) or through the middle meningeal artery (2/12, 17%) when ophthalmic artery obstruction was present from initial IAC elsewhere. Each case received median 3 IAC cycles of Melphalan alone (4/12, 33%) or combination Melphalan and Topotecan (8/12, 67%). At median follow-up of 7 months (range 3-31 months), complete tumor control was achieved in 10 eyes (83%) and globe salvage in 9 eyes (75%). Three eyes underwent enucleation for persistent subretinal seeds (n=2) or neovascular glaucoma without viable tumor on histopathology (n=1). There was no case of cerebrovascular stroke, systemic metastasis, or death.

 
Conclusions
 

Rescue IAC following tumor recurrence after initial IAC provided 83% tumor control and 75% globe salvage in this series.  

 
Regression of subretinal seeds after rescue intraarterial chemotherapy. (A) Retcam photograph upon presentation with total retinal detachment secondary to a large exophytic retinoblastoma. (B) Main tumor regression after 3 sessions of intraarterial Melphalan 5mg. (C). Recurrent subretinal seeds at the superior arcade and (D) in the inferior peripheral retina. (E & F) Complete regression of the subretinal seeds after rescue intraarterial chemotherapy using Melphalan 5mg and Topotecan 1mg.
 
Regression of subretinal seeds after rescue intraarterial chemotherapy. (A) Retcam photograph upon presentation with total retinal detachment secondary to a large exophytic retinoblastoma. (B) Main tumor regression after 3 sessions of intraarterial Melphalan 5mg. (C). Recurrent subretinal seeds at the superior arcade and (D) in the inferior peripheral retina. (E & F) Complete regression of the subretinal seeds after rescue intraarterial chemotherapy using Melphalan 5mg and Topotecan 1mg.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×